Scienture Holdings Q3 revenue jumps on REZENOPY launch

By Reuters News


Overview

  • US specialty pharma firm's Q3 2026 revenue grew yr/yr, driven by REZENOPY launch

  • Q3 gross profit rose 77.5% yr/yr to $1.02 mln, with gross margin at 81.3%


Outlook

  • Company expects to achieve breakeven operating income of $6 mln and profitability in 2027


Result Drivers

  • REZENOPY LAUNCH - Initial wholesale shipments of REZENOPY after its August 2026 launch generated about $925,000 in Q3 revenue and were the primary driver of sequential revenue growth

  • ARBLI SALES EXPANSION - Continued commercialization of Arbli, including increased formulary placements and growing institutional access, contributed to revenue growth; Arbli wholesale unit sales rose 74% sequentially

  • DISTRIBUTION AGREEMENTS - New direct customer distribution agreement for REZENOPY expanded access to about 2,000 opioid treatment clinics and addiction centers, broadening commercial reach beyond wholesale channels


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Gross Margin

81.30%

Q3 Gross Profit

$1.02 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Scienture Holdings Inc is $6.00, about 106.9% above its November 13 closing price of $2.90


Reuters Recommended Reads

  • Nov 16 - ALX Oncology Q3 net loss per share narrows

  • Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.